Prime Medicine, Inc. (PRME) Tops Q2 EPS by 3c

Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.46), $0.03 better than the analyst estimate of ($0.49).

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

You May Also Be Interested In

• JPMorgan Downgrades Shenzhen Inovance Tech (300124:CH) to Neutral
• Societe Generale SA (GLE:FP) (SCGLY) PT Raised to EUR83 at JPMorgan
• TUI AG (TUI1:GR) (TUIFY) PT Lowered to EUR10.10 at Deutsche Bank